News & Views
Research Focused on CNS Disease
Jan 08 2019
Domain Therapeutics (Strasbourg) and Boehringer Ingelheim are collaborating in a multi-target drug discovery and licensing agreement on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.
Domain Therapeutics will use its proprietary platforms, DTect-All™ and bioSens-All™, which enable characterisation of small molecule GPCR binders for the screening of potential lead compounds. Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details were not disclosed.
“We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts,” said Dr Bernd Sommer, Global Head, CNS Diseases Research at Boehringer Ingelheim. “We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”
“With its focus on emerging science and breakthrough medicines, we are enthusiastic to be working with Boehringer Ingelheim,” said Pascal Neuville, CEO of Domain Therapeutics. “We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets and coupled with Boehringer Ingelheim’s strength and expertise, their rapid advancement into the clinic.”
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 28 2024 Montreal, Quebec, Canada
May 05 2024 Seville, Spain
InformEx Zone at CPhl North America
May 07 2024 Pennsylvania, PA, USA
May 14 2024 Oklahoma City, OK, USA
May 15 2024 Birmingham, UK